Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric D Bateman

Showing results (71-80 of 161) with videos related to

Pageof 17
Sort By:
Respiratory Medicine|August 6, 2016
Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic statusHuib A M Kerstjens, Petra Moroni-Zentgraf, Donald P Tashkin, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 5, 2020
Transition from Restrictive to Obstructive Lung Function Impairment During Treatment and Follow-Up of Active TuberculosisBrian W Allwood, Elizna Maasdorp, Grace J Kim, et al.
Allergy|March 10, 2025
Asthma Control and Risk Factors for Poor Asthma Outcomes in Chinese Asthma Patients: Baseline Analysis of a Multi-Centre, Single-Arm Study (CARE4ALL)Kewu Huang, Meishan Liu, Wenjun Wang, et al.
The European Respiratory Journal|February 25, 2012
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroidsJan Lötvall, Eric D Bateman, Eugene R Bleecker, et al.
The European Respiratory Journal|October 19, 2013
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthmaPaul M O'Byrne, Eugene R Bleecker, Eric D Bateman, et al.
Respiratory Medicine|November 8, 2016
Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analysesDonald P Tashkin, Eric D Bateman, Paul Jones, et al.
BMC Pulmonary Medicine|January 21, 2014
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyKenneth R Chapman, Kai-Michael Beeh, Jutta Beier, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 9, 2018
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal PolypsSteven F Weinstein, Rohit K Katial, Philip Bardin, et al.
Journal of Negative Results in Biomedicine|June 15, 2014
Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroidsJan Lötvall, Eric D Bateman, William W Busse, et al.
The New England Journal of Medicine|September 4, 2012
Tiotropium in asthma poorly controlled with standard combination therapyHuib A M Kerstjens, Michael Engel, Ronald Dahl, et al.
Pageof 17

Showing results (71-80 of 161) with videos related to

Sort By:
Pageof 17
Respiratory Medicine|August 6, 2016
Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic statusHuib A M Kerstjens, Petra Moroni-Zentgraf, Donald P Tashkin, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 5, 2020
Transition from Restrictive to Obstructive Lung Function Impairment During Treatment and Follow-Up of Active TuberculosisBrian W Allwood, Elizna Maasdorp, Grace J Kim, et al.
Allergy|March 10, 2025
Asthma Control and Risk Factors for Poor Asthma Outcomes in Chinese Asthma Patients: Baseline Analysis of a Multi-Centre, Single-Arm Study (CARE4ALL)Kewu Huang, Meishan Liu, Wenjun Wang, et al.
The European Respiratory Journal|February 25, 2012
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroidsJan Lötvall, Eric D Bateman, Eugene R Bleecker, et al.
The European Respiratory Journal|October 19, 2013
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthmaPaul M O'Byrne, Eugene R Bleecker, Eric D Bateman, et al.
Respiratory Medicine|November 8, 2016
Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analysesDonald P Tashkin, Eric D Bateman, Paul Jones, et al.
BMC Pulmonary Medicine|January 21, 2014
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyKenneth R Chapman, Kai-Michael Beeh, Jutta Beier, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 9, 2018
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal PolypsSteven F Weinstein, Rohit K Katial, Philip Bardin, et al.
Journal of Negative Results in Biomedicine|June 15, 2014
Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroidsJan Lötvall, Eric D Bateman, William W Busse, et al.
The New England Journal of Medicine|September 4, 2012
Tiotropium in asthma poorly controlled with standard combination therapyHuib A M Kerstjens, Michael Engel, Ronald Dahl, et al.
Pageof 17